Publisher Correction: EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Food Insecurity Is Highly Prevalent Amongst Patients With Chronic Liver Disease in Northern England: A Cross-Sectional Analysis.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
   Article
2. Electrocardiographic P-Wave Indices in Metabolic Dysfunction-Associated Fatty Liver Disease and Their Relationship to Hepatic Fibrosis Risk.Journal of clinical medicine · 2025
   Article

Corrections and comments

• Erratum for
  EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.2024

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.